Answers are grounded in this paper and cite their sources.
INTRODUCTION: In adult patients, anti-muscle-specific receptor tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) frequently presents with bulbar symptoms and tends to progress to myasthenic crisis, although data in pediatric patients are limited. Pediatric-onset MuSK-MG is rare, and a standard treatment approach has not been established. Here, we report a pediatric-onset case of MuSK-MG in which combination immunotherapy improved symptoms, including dysphagia. CASE PRESENTATION: A 15-year-old girl presented with diplopia that had begun 2 years prior, followed by gradual worsening of dysphagia and dysarthria. A videofluoroscopic swallowing study (VFSS) demonstrated inadequate soft palate elevation, poor pharyngeal contraction, repeated swallowing, laryngeal penetration, and residue in the epiglottic vallecula and pyriform sinus. She tested positive for anti-muscle-specific receptor tyrosine kinase antibodies (anti-MuSK antibodies) and was diagnosed with MuSK-MG. Treatment with intravenous immunoglobulin, intravenous methylprednisolone, and oral prednisolone and tacrolimus led to improvement in her symptoms, including dysphagia, starting 3 weeks after initiation. CONCLUSION: MuSK-MG may be responsive to treatment even 2 years after symptom onset. Anti-MuSK antibodies testing should be considered in patients with progressive dysphagia and dysarthria, particularly when bulbar symptoms are unexplained. VFSS was useful for objectively assessing the severity of dysphagia and its improvement.
No takes yet. Share an insight, caveat, or question.
Handa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: